Dr. Agarwal's Health Care Limited Reports Strong Q1 FY27 Results, Announces Nigerian Subsidiary Plans and Auditor Appointments

Dr. Agarwal's Health Care Limited Reports Strong Q1 FY27 Results, Announces Nigerian Subsidiary Plans and Auditor Appointments​

Chennai: Dr. Agarwal's Health Care Limited, a major player in India's eye care service industry operating 304 facilities across multiple countries, has announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported robust growth across key metrics, with Revenue from Operations rising by 26.0% year-on-year (YoY) to ₹614 Crores, while Total Income grew by 23.9% YoY reaching ₹620 Crores.

The consolidated results demonstrate strong profitability, with EBITDA growing by 25.2% YoY to ₹177 Crores, and Profit after Tax (PAT) increasing by 44.6% YoY to ₹55 Crores.

Financial Highlights for Q1 FY2027​

The company's performance in the quarter, as compared to prior periods, is summarized below:

Operational Growth and Activities​

Operationally, the company continued its expansion trajectory. As of June 30, 2026, Dr. Agarwal's Health Care Limited maintained a network of 304 facilities, adding 18 new locations during the quarter, which included one Tertiary, fifteen Secondary, and two Primary facilities.

The company performed 91,082 surgeries in Q1 FY2027, marking a 15.5% increase YoY. Revenue from Operations was derived from both services and products; services contributed 77.7% and products accounted for 22.3%. The revenue generated from operations in India stood at ₹552 Cr (25.3% growth), while revenue from mature facilities reached ₹485 Cr (37.1% growth).

Commenting on the results, Dr. Adil Agarwal, CEO of Dr. Agarwal's Health Care Limited, noted that the quarter was exceptional across multiple fronts. He highlighted that the company recorded its highest sequential quarter-on-quarter revenue growth and set a record by launching 16 greenfield surgical facilities in a single quarter. "Profit after tax rose to ₹55 crore, up 44.6% year-on-year," he stated.

Strategic Appointments and Expansion Plans​

The Board of Directors meeting on August 04, 2026, approved several key corporate decisions regarding auditing and future expansion:

Auditor and Auditor Committee Appointments:
The board confirmed the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors of the Company. This firm is set to hold office from the conclusion of the ensuing 16th Annual General Meeting (AGM) until the conclusion of the 20th AGM, pending shareholder approval.

Additionally, the company appointed M/s. KPMG Assurance and Consulting Services LLP as Internal Auditors for the financial year 2026-27 following a rotation policy. Furthermore, M/s. B Y & Associates, Practicing Cost Accountants, were re-appointed as the Cost Auditors for 2026-27.

New International Venture:
The company is also planning significant international expansion through its subsidiary, Orbit Healthcare Services (Mauritius) Limited. The company has proposed incorporating a wholly owned subsidiary in Nigeria to expand its operations in the region. This venture will be focused on Ophthalmology / Eye Care Related Sales & Services and is scheduled for incorporation, subject to necessary regulatory and governmental approvals required under Nigerian and Mauritian law.

Subsidiary Listing Details​

The Group operates across various entities as part of its operational structure. The subsidiaries include Dr. AQarwal's Eve Hospital Limited, Dr. Thind Eve Care Private Limited, Orbit Healthcare Services (Mauritius) Limited, Elisar Life Sciences Private Limited, Aditya Jyot Eye Hospital Private Limited, and IdeaRx Services Private Limited (which recently ceased being an associate after amending its Articles of Association).

AGARWALEYE Stock Price Movement​

Shares of Dr. Agarwal's Health Care Limited are edging higher to ₹497.2 as of 2:15 PM today, rallying in live trading after gaining 2.88%. The stock has seen active participation with 128,085 shares traded so far during the day.